Travis Alvin Thompson Sells 6,256 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, October 3rd, Travis Alvin Thompson sold 153 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $22.26, for a total value of $3,405.78.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $22.58 on Friday. The stock’s 50-day simple moving average is $24.55 and its 200 day simple moving average is $23.18. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -6.86 and a beta of 0.89. Bicycle Therapeutics plc has a 52-week low of $13.07 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.26) EPS. On average, research analysts forecast that Bicycle Therapeutics plc will post -3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BCYC has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Stephens initiated coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.13.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the last quarter. L & S Advisors Inc increased its stake in Bicycle Therapeutics by 2.4% in the 3rd quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock worth $1,352,000 after acquiring an additional 1,400 shares during the last quarter. Assetmark Inc. bought a new position in Bicycle Therapeutics in the 3rd quarter worth about $34,000. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Bicycle Therapeutics by 0.6% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after acquiring an additional 4,976 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.